CN109715788A - 用于免疫疗法的t细胞组合物 - Google Patents

用于免疫疗法的t细胞组合物 Download PDF

Info

Publication number
CN109715788A
CN109715788A CN201780053540.8A CN201780053540A CN109715788A CN 109715788 A CN109715788 A CN 109715788A CN 201780053540 A CN201780053540 A CN 201780053540A CN 109715788 A CN109715788 A CN 109715788A
Authority
CN
China
Prior art keywords
cell
antigen
virus
composition
target antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053540.8A
Other languages
English (en)
Chinese (zh)
Inventor
A.E.斯莱恩茨
T.Y.纳卡加瓦
M.A.赫尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kingius Biotechnology Co
Original Assignee
Kingius Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kingius Biotechnology Co filed Critical Kingius Biotechnology Co
Publication of CN109715788A publication Critical patent/CN109715788A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780053540.8A 2016-06-28 2017-06-28 用于免疫疗法的t细胞组合物 Pending CN109715788A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662355533P 2016-06-28 2016-06-28
US201662355506P 2016-06-28 2016-06-28
US201662355458P 2016-06-28 2016-06-28
US62/355458 2016-06-28
US62/355506 2016-06-28
US62/355533 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
CN109715788A true CN109715788A (zh) 2019-05-03

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053540.8A Pending CN109715788A (zh) 2016-06-28 2017-06-28 用于免疫疗法的t细胞组合物

Country Status (11)

Country Link
US (2) US20200237819A1 (https=)
EP (1) EP3487990A4 (https=)
JP (3) JP7034955B2 (https=)
KR (1) KR20190037243A (https=)
CN (1) CN109715788A (https=)
AU (3) AU2017290119A1 (https=)
CA (1) CA3068387A1 (https=)
IL (1) IL263896A (https=)
MX (1) MX2019000180A (https=)
SG (1) SG11201811745UA (https=)
WO (1) WO2018005712A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113481157A (zh) * 2021-07-21 2021-10-08 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113512529A (zh) * 2021-07-21 2021-10-19 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116A (zh) * 2021-07-21 2021-10-29 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
IL294055A (en) * 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11793867B2 (en) * 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP7198602B2 (ja) * 2018-07-11 2023-01-04 カワサキモータース株式会社 自動二輪車
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
AU2019314888A1 (en) * 2018-07-31 2021-02-18 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (TURICs)
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
JP7495137B2 (ja) * 2018-08-10 2024-06-04 ユーティレックス カンパニー リミテッド 癌抗原特異的細胞傷害性ｔ細胞
US20210388317A1 (en) * 2018-10-26 2021-12-16 Shinshu University High-efficiency method for producing genetically modified cells
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US20220064597A1 (en) * 2018-12-18 2022-03-03 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
EP3908293A4 (en) * 2019-01-07 2023-01-11 Children's National Medical Center EX VIVO ACTIVATED T LYMPHOCYTE COMPOSITIONS AND METHODS OF USE THEREOF
AU2020221310B2 (en) * 2019-02-14 2025-10-16 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
CA3132028A1 (en) * 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
WO2020243729A1 (en) * 2019-05-31 2020-12-03 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
CA3145196A1 (en) * 2019-06-24 2020-12-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
CA3162703A1 (en) * 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US20230028788A1 (en) * 2019-12-23 2023-01-26 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2023039410A1 (en) * 2021-09-08 2023-03-16 KSQ Therapeutics, Inc. Lymphocyte potency assay
US20250325668A1 (en) * 2021-10-08 2025-10-23 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬
WO2023178140A2 (en) * 2022-03-18 2023-09-21 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
KR102566680B1 (ko) * 2022-09-28 2023-08-14 (주)포에버엔케이 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023377A1 (en) * 1998-05-11 2004-02-05 Mario Assenmacher Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
US20130058909A1 (en) * 2010-05-17 2013-03-07 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
US20140099341A1 (en) * 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US20160068811A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble Antibody Complexes For T Cell or NK Cell Activation and Expansion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2327487C2 (ru) 2002-08-08 2008-06-27 Бейлор Колледж Оф Медисин Выделение и идентификация т-клеток
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US10993997B2 (en) * 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3322801A1 (en) * 2015-07-15 2018-05-23 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023377A1 (en) * 1998-05-11 2004-02-05 Mario Assenmacher Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
US20130058909A1 (en) * 2010-05-17 2013-03-07 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
US20140099341A1 (en) * 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US20160068811A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble Antibody Complexes For T Cell or NK Cell Activation and Expansion

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN113481157A (zh) * 2021-07-21 2021-10-08 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113512529A (zh) * 2021-07-21 2021-10-19 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116A (zh) * 2021-07-21 2021-10-29 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN113512529B (zh) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法

Also Published As

Publication number Publication date
JP2019519246A (ja) 2019-07-11
AU2017290119A1 (en) 2019-01-24
SG11201811745UA (en) 2019-01-30
US20230145991A1 (en) 2023-05-11
EP3487990A1 (en) 2019-05-29
JP2022066355A (ja) 2022-04-28
AU2026202260A1 (en) 2026-04-09
EP3487990A4 (en) 2020-07-29
MX2019000180A (es) 2019-11-05
WO2018005712A1 (en) 2018-01-04
AU2023254998A1 (en) 2023-11-16
KR20190037243A (ko) 2019-04-05
JP2024103547A (ja) 2024-08-01
CA3068387A1 (en) 2018-01-04
JP7034955B2 (ja) 2022-03-14
US20200237819A1 (en) 2020-07-30
IL263896A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US20230145991A1 (en) T cell compositions for immunotherapy
Parkhurst et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression
AU2011212794B2 (en) ICOS critically regulates the expansion and function of inflammatory human Th17 cells
Wardell et al. Harnessing the biology of regulatory T cells to treat disease
Swain et al. Homeostasis and the age-associated defect of CD4 T cells
CN110662834B (zh) 使用转化的t细胞培养自然杀伤细胞的方法
EP2899269B1 (en) Method for cloning t cell receptor
KR20170121178A (ko) 보편적인 살해 t-세포
KR20170067751A (ko) 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
US20260078340A1 (en) Scaffolds with stabilized mhc molecules for immune-cell manipulation
JP2022512538A (ja) Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法
JP2018511320A (ja) 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法
Adair et al. Avidity of human T cell receptor engineered CD4+ T cells drives T-helper differentiation fate
US20240252644A1 (en) Person-tailored t cell composition targeting merkel cell carcinoma
Reimann et al. Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains
CN102596209A (zh) 含有短暂性存活ctl的医药品组合物
JP6508873B2 (ja) 抗原特異的ｔ細胞受容体の取得方法
Titov et al. Adoptive Immunotherapy beyond CAR T-Cells. Cancers 2021, 13, 743
Sakellariou-Thompson Bringing Til Therapy Beyond Melanoma: Advancing The Treatment of Advanced Pancreatic and Ovarian Cancers
RU2023104429A (ru) Композиции и способы для производства t-клеток
Bleakley et al. Activation induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8 Tcells responding to antigen without requiring knowledge of epitope specificities
HK40003131A (zh) Cacna1h衍生的肿瘤抗原多肽及其应用
HK40010495A (en) Col14a1-derived tumour antigen polypeptide and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination